---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817)"
date: 2026-02-05 18:57:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-26363
original_published: 2023-11-30 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817)

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 30, 2023 00:00 UTC
**Document Number:** 2023-26363

## Summary

The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Injection (new drug application (NDA) 209817) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/30/2023-26363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuzyra-injection-new-drug)
- API: https://www.federalregister.gov/api/v1/documents/2023-26363

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
